Marc Verlinden, Vice-President and Managing Director for Qualiphar-Gifrer, said: "We are pleased to announce the establishment of our offices in Dubai through our partnership agreement with DuBiotech. This is a major feat that will enable us to meet the increasing demand for our pharmaceutical products in the Middle East.
"Setting up operations in Dubai will allow us to provide the best possible service to our affiliates in the region, as well as to our future partners in the Middle-East, Asia and Africa."
Dr. Abdulqader Al Khayat, Executive Director of DuBiotech, said: "Qualiphar-Gifrer has acknowledged the enormous potential that Dubai offers, particularly in biotechnology, and we are glad DuBiotech is their partner of choice in this first step towards global expansion.
"DuBiotech is committed to creating an advanced technical and community infrastructure for the life sciences industry. In this regard, we are confident Qualiphar-Gifrer will add considerable value to our offerings through conducting research and development on new pharmaceutical products and existing product formulations."
Launched in February 2005, Dubai Biotechnology and Research Park aims to set up a biotechnology industry cluster with appropriate infrastructure, facilities and services for incubators, R&D labs, biotech-related educational institutions, suppliers, biotech and pharmaceutical manufacturing companies.
Offering a complete value chain to help companies set up operations, DuBiotech currently hosts more than 35 licensed firms. The free zone is working closely with the UAE Ministry of Health, the Dubai Health Authority, and other relevant regulatory bodies to further grow the life sciences industry in the country.
Browse
related articles

Posted by Anne-Birte Stensgaard, Senior News Editor
